Adimmune (TPE:4142) Research & Development: NT$237 Mil (TTM As of Dec. 2025)


TPE:4142 Adimmune Corp TPE:4142
55 GF Score
Price NT$16.80
GF Value NT$25.40
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Adimmune Research & Development?

Adimmune TPE:4142 -1.75% 55 Research & Development is NT$237 Mil as of Dec. 2025. GuruFocus rates TPE:4142 with a GF Score™ of 55/100 and a GF Value™ of NT$25.40 (Possible Value Trap). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Adimmune's Research & Development for the three months ended in Dec. 2025 was NT$75 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$237 Mil.

Adimmune  (TPE:4142) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Adimmune Research & Development Related Terms

Adimmune Research & Development Historical Data

* Premium members only.

The historical data trend for Adimmune's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adimmune Research & Development Chart

Adimmune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 321.28 346.42 296.93 292.05 237.40

Adimmune Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 103.60 53.32 70.94 38.46 74.68
TPE:4142
55GF Score
Adimmune Corp TPE:4142
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adimmune Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$237 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$237 Mil mean?
Adimmune (TPE:4142) has a Research & Development of NT$237 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Adimmune and its competitors.
Is Adimmune's Research & Development too high?
Adimmune's current Research & Development is NT$237 Mil. Overall, Adimmune has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Adimmune's Research & Development compare to VRTX and REGN?
Adimmune's Research & Development of NT$237 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Adimmune and its competitors. Adimmune's current Research & Development is NT$237 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adimmune stock overvalued right now?
Based on GuruFocus' analysis, Adimmune (TPE:4142) is currently considered Possible Value Trap. The stock's GF Value™ is NT$25.40, compared to a current price of NT$16.80 — trading 33.9% below its estimated fair value. The current Research & Development is NT$237 Mil. Adimmune's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Adimmune (TPE:4142), the current Research & Development is NT$237 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adimmune (TPE:4142) Overvalued in 2026?

Based on GuruFocus' analysis, Adimmune stock appears to be undervalued. The current stock price of NT$16.80 is trading 33.9% below its estimated GF Value™ of NT$25.40. GuruFocus considers Adimmune to be Possible Value Trap.

Key valuation signals for TPE:4142:

  • Research & Development: NT$237 Mil
  • GF Value™: NT$25.40 vs. price of NT$16.80 (33.9% below fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the TPE:4142 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adimmune Business Description

Address Tanxing Road, No. 3, Section 1, Tanzi District, Taichung City, TWN, 427003
Adimmune Corp is engaged in the research and development, processing, manufacturing, and trading of serum, vaccines, testing reagents, biologicals, and other bacterial fluids, as well as western medicines, animal medicines, chemicals, and feed additives. Its segments are separated by business as Adimmune Corporation, which generates maximum revenue and is engaged in the manufacturing of influenza vaccines with EU GMP and US FDA certificates in Taiwan. Its products include Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, and others, and Enimmune Corporation. The Group's revenue is mainly from the manufacturing and trading of vaccines, modern medicine products and testing reagents, as well as entrusted packing of vaccines.
55GF Score

Get the complete analysis for TPE:4142

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.80
Price
NT$25.40
GF Value